# Investigate the Effect of AZD1656 on the Pharmacokinetics of Pioglitazone and Vice Versa in Type 2 Diabetes Mellitus

> **NCT01082120** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 28 (estimated)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** AZD1656
- **DRUG:** Pioglitazone

## Key facts

- **NCT ID:** NCT01082120
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-02
- **Primary completion:** 2010-05
- **Final completion:** 2010-05
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2010-07-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01082120

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01082120, "Investigate the Effect of AZD1656 on the Pharmacokinetics of Pioglitazone and Vice Versa in Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01082120. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*